Revolution Medicines, Warrant Stock Fundamentals
| RVMDW Stock | 0.39 0.04 9.30% |
Revolution Medicines, Warrant fundamentals help investors to digest information that contributes to Revolution Medicines,'s financial success or failures. It also enables traders to predict the movement of Revolution Stock. The fundamental analysis module provides a way to measure Revolution Medicines,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revolution Medicines, stock.
At this time, Revolution Medicines,'s Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 49.9 M in 2024, whereas Interest Expense is likely to drop slightly above 287.9 K in 2024. Revolution | Select Account or Indicator |
Revolution Medicines, Warrant Company Return On Equity Analysis
Revolution Medicines,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Revolution Medicines, Return On Equity | -0.47 |
Most of Revolution Medicines,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revolution Medicines, Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Revolution Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Revolution Medicines, Warrant has a Return On Equity of -0.4718. This is 98.03% lower than that of the Biotechnology sector and 98.71% lower than that of the Health Care industry. The return on equity for all United States stocks is 52.19% higher than that of the company.
Revolution Medicines, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Revolution Medicines,'s current stock value. Our valuation model uses many indicators to compare Revolution Medicines, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Revolution Medicines, competition to find correlations between indicators driving Revolution Medicines,'s intrinsic value. More Info.Revolution Medicines, Warrant is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At this time, Revolution Medicines,'s Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Revolution Medicines, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Revolution Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revolution Medicines,'s direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revolution Medicines, could also be used in its relative valuation, which is a method of valuing Revolution Medicines, by comparing valuation metrics of similar companies.Revolution Medicines, is currently under evaluation in return on equity category among its peers.
Revolution Medicines, Current Valuation Drivers
We derive many important indicators used in calculating different scores of Revolution Medicines, from analyzing Revolution Medicines,'s financial statements. These drivers represent accounts that assess Revolution Medicines,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Revolution Medicines,'s important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 2.6B | 1.8B | 1.9B | 3.2B | 3.4B | |
| Enterprise Value | 1.7B | 2.6B | 1.8B | 1.8B | 2.6B | 1.4B |
Revolution Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (845.95) % | ||||
| Number Of Shares Shorted | 4.66 K | ||||
| Revenue | 11.58 M | ||||
| EBITDA | (430.58 M) | ||||
| Net Income | (436.37 M) | ||||
| Total Debt | 87.94 M | ||||
| Book Value Per Share | 9.34 X | ||||
| Cash Flow From Operations | (350.57 M) | ||||
| Number Of Employees | 490 | ||||
| Beta | 1.4 | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 1.74 B | ||||
| Net Asset | 2.06 B |
About Revolution Medicines, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revolution Medicines, Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revolution Medicines, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revolution Medicines, Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -54.6 M | -51.8 M | |
| Total Revenue | 11.6 M | 11 M | |
| Cost Of Revenue | 411.2 M | 431.8 M | |
| Stock Based Compensation To Revenue | 5.33 | 5.60 | |
| Sales General And Administrative To Revenue | 6.53 | 6.86 | |
| Research And Ddevelopement To Revenue | 36.54 | 38.37 | |
| Capex To Revenue | 0.67 | 0.70 | |
| Revenue Per Share | 0.10 | 0.10 | |
| Ebit Per Revenue | (42.07) | (39.97) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revolution Stock Analysis
When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.